Mankind Pharma Limited - IPO Analysis Positives & Negatives
Вставка
- Опубліковано 24 сер 2024
- About Mankind Pharma IPO:
- Mankind Pharma is India’s fourth largest pharmaceutical company in terms of Domestic Sales and third largest in terms of sales volume for MAT December 2022. It engages in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories.
Complete Fundamental Stock Analysis Tool - Stock-o-meter:
investyadnya.i...
Research Based Ready-made Model Portfolios:
investyadnya.i...
Comprehensive Mutual Fund Reviews:
investyadnya.i...
Yadnya Books and eBooks now available:
On Amazon - amzn.to/2XKtlks
On our website - investyadnya.i...
Find us on Social Media and stay connected:
Blog - blog.investyad...
Telegram - t.me/InvestYadnya
Facebook Page - / investyadnya
Facebook Group - goo.gl/y57Qcr
Twitter - / investyadnya
LinkedIn - / investyadnya
#mankindpharma #mankindpharmaipo #ipoanalysis
#InvestYadnya #YIA
LEGAL DISCLAIMER:
Use of this information is at the user's own risk. The Company and its directors, associates and employees will not be liable for any loss or liability incurred to the user due to investments made or decisions taken based on the information provided herein. The investment discussed or views expressed herein may not be suitable for all investors. The users should rely on their own research and analysis and should consult their investment advisors to determine the merit, risks and suitability of recommendation. Past performance is not a guarantee for future performance or future results. Information herein is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The images used may be copyright of the company or third party. As a condition to using the services, the user agrees to the terms of use of the website and the services.
DISCLOSURES UNDER SEBI (RESEARCH ANALYST) REGULATIONS, 2014:
Yadnya Academy Pvt. Ltd. (InvestYadnya) is registered with SEBI under SEBI (Research Analyst) Regulations, 2014 with registration no. INH000008349.
Disclosure with regard to ownership and material conflicts of interest
1. Neither Research Analyst nor the entity nor his associates or relatives have any financial interest in the subject Company;
2. Neither Research Analyst nor the entity nor its associates or relatives have actual / beneficial ownership of one per cent or more securities of the subject Company, at the end of the month immediately preceding the date of publication of the research report or date of public appearance;
3. Neither Research Analyst nor the entity nor its associates or his relatives have any other material conflict of interest at the time of publication of the research report or at the time of public appearance.
Disclosure with regard to receipt of Compensation
1. The Research Entity and its associates have not received compensation from the subject company in the past twelve months.
2. The subject company is not or was not a client during the twelve months preceding the date of recommendation.
Mankind Pharma is one of the best Pharma Companies... Employees on ground level work hard & earn a lot. 😊
One of the best ipo review heard so far. Clear and unbiased. Most importantly the conclusion was excellent. Really appreciate your work and best wishes to the entire team
You have explained everything in ver simple words for common man . Thank you for genuine info. Appreciate it👏
Sir aapka session bahut aacha hota hai
Excellent analysis. This is what we can expect from an expert...finfluencers can never bring such analysis.....baap baap hota h...😂😂
Uncle knows how they bought their products back in years
Sir u r great! Much needed video
This was a good take on the company. Thank you
Good overview;best advice
Yes sir ur right we should wait for mankind stock
Thank you for your wonderful video..
Very good analysis sir thanks
Good analysis, sage advice.
Thanks for sharing..
Very informative sir🙏
Superb advice
Great analysis 👌
Very nice
Could be profitable in the long term
Good Analysis
You have not discussed about the valuation of ipo is it worth that price
Please make video on kpit tech
Sir, I have mailed you related terms of Gertner report. Still I haven't got any confirmation from yadnya investment
I belong to pharma field...your analysis is in depth analysis..not the analysis of DRHP
Mankind pharma limited should invest in Pakistan .
NOTHING On nThe Table ..... ..... Just Avoid
12.50 sec thik hai 😂
1 st view